Financial Advocates Investment Management Has $72,000 Position in INmune Bio, Inc. (NASDAQ:INMB)

Financial Advocates Investment Management boosted its holdings in INmune Bio, Inc. (NASDAQ:INMB) by 14.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 15,500 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Financial Advocates Investment Management owned about 0.07% of INmune Bio worth $72,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of INMB. Jane Street Group LLC acquired a new stake in INmune Bio in the 3rd quarter valued at $79,000. Sanctuary Advisors LLC purchased a new position in INmune Bio during the 3rd quarter worth $113,000. Barclays PLC boosted its holdings in INmune Bio by 601.9% during the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after acquiring an additional 24,906 shares during the last quarter. Fermata Advisors LLC boosted its holdings in INmune Bio by 10.0% during the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after acquiring an additional 4,267 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in INmune Bio during the 3rd quarter worth $249,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $9.12 on Tuesday. The company’s 50-day moving average is $6.22 and its 200 day moving average is $6.08. The company has a market capitalization of $202.19 million, a P/E ratio of -4.18 and a beta of 1.87. INmune Bio, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of INmune Bio in a report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price objective on the stock. Alliance Global Partners assumed coverage on shares of INmune Bio in a report on Monday, October 21st. They set a “buy” rating and a $20.00 price objective on the stock. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, INmune Bio currently has a consensus rating of “Buy” and an average price target of $20.75.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.